Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
49.58
+0.73 (+1.49%)
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
Next >
Collegium to Participate in Upcoming Investor Conferences
November 12, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
November 06, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
October 29, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
October 23, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
October 22, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
October 13, 2025
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 –
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
August 28, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
August 25, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
August 07, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
July 24, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces $150 Million Share Repurchase Program
July 07, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
May 19, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Collegium Announces $25 Million Accelerated Share Repurchase Program
May 12, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
May 08, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
April 24, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
March 27, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
March 17, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
March 10, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
March 04, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
February 27, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
February 13, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Appoints Nancy S. Lurker to its Board of Directors
February 05, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Provides 2025 Financial Guidance and Business Update
January 08, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
November 12, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Record Third Quarter 2024 Financial Results
November 07, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Appoints Vikram Karnani as Chief Executive Officer
November 07, 2024
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.